Novo Nordisk A/S NVO Moat

Key data

The moat

Novo Nordisk's moat is a century of insulin manufacturing turned into a lead in peptide medicine. Making a GLP-1 at scale is a manufacturing problem as much as a chemistry one, and Novo built the capacity before the demand arrived. Patents protect the molecule, regulatory approval protects the indication, and prescriber habit protects the refill.

Around that sits a payer and distribution position built over decades of diabetes care, which is how a new obesity medicine reached formularies quickly.

What it produced is obesity sales that grew 26% in a year to DKK 82.3B, built on a molecule the company took two decades to bring from diabetes into weight.

Widening or narrowing

The growth engine is decelerating and the base business has stopped growing.

Obesity growth fell from 31% to 15% across the period, four measurement points all in one direction. Diabetes care, the century-old franchise, turned slightly negative in the most recent quarter.

The share figure is the harder number because it is measured externally rather than claimed. Diabetes value share fell 3.6 percentage points to 30.1% on a moving annual basis, so it is not a single quarter's noise, and a moving annual total moves slowly by construction, meaning a 3.6 point fall represents a great deal of underlying movement.

The overrated case, and it is the price direction. The company states that American obesity sales grew 4% at constant currency driven by volume growth partly offset by lower realised prices. That pattern repeats across regions. Growth is coming from more prescriptions at lower net prices, which is the opposite of what a patent-protected moat is supposed to deliver. A pricing agreement with the American administration signed in November 2025 to expand access and lower costs points the same way.

On profit pool, Novo takes a branded medicine's price for a drug that changes what a patient weighs, with the payer between it and the patient. A very fat slice historically, and the realised price line says it is thinning while the volume line says demand is not the problem.

The moat is narrowing.